Product Information
REPAGLINIDE 1 MG TABLET is a generic product labeled by American Health Packaging, priced at $0.0987 per EA under NDC 60687056021. Its NADAC has been published 308 times since Nov 11, 2020.
FDA first approved this application on Jan 22, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Repaglinide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1 mg/1
Manufacturer
American Health PackagingNDC
60687056021
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
REPAGLINIDEApproval Type
Generic (ANDA)
FDA Application
ANDA203820FDA Approved
1/22/2014
TE Code
AB
On Market Since
9/17/2020
Pharmacological Classes
Price Statistics
The NADAC for REPAGLINIDE 1 MG TABLET has been published 308 times since Nov 11, 2020, and over the history we have for it it has declined 39.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0987 per EA |
|---|---|
| All-time high | $0.2255 (Dec 16, 2020) |
| All-time low | $0.0800 (Mar 18, 2026) |
| 52-week high | $0.1005 |
| 52-week low | $0.0800 |
| Median price | $0.1206 |
| Average price | $0.1243 |
| Largest weekly change | +37.7% (Nov 18, 2020) |
| Weeks tracked | 308 |
| Tracking since | Nov 11, 2020 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
American Health Packaging manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Repaglinide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Glinide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of REPAGLINIDE 1 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for REPAGLINIDE 1 MG TABLET, manufactured by American Health Packaging, is $0.0987 per EA (NDC 60687056021), effective Sep 30, 2026.
How has the price of REPAGLINIDE 1 MG TABLET changed over time?
Over the history we have for it, the NADAC for REPAGLINIDE 1 MG TABLET has declined 39.7%. It has been tracked across 308 weekly CMS publications since Nov 11, 2020.
What are the highest and lowest recorded NADAC prices for REPAGLINIDE 1 MG TABLET?
Since Nov 11, 2020, the NADAC for REPAGLINIDE 1 MG TABLET has ranged from a low of $0.0800 (Mar 18, 2026) to a high of $0.2255 (Dec 16, 2020), with a median of $0.1206 per EA.
Are there cheaper alternatives to REPAGLINIDE 1 MG TABLET?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as REPAGLINIDE 1 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures REPAGLINIDE 1 MG TABLET?
REPAGLINIDE 1 MG TABLET (NDC 60687056021) is labeled by American Health Packaging, and CMS classifies it as a generic product.